- About Us
- Nano-Social Network
- Nano Consulting
- My Account
March 3rd, 2005
On Monday, Elan's (ELN) stock price dropped 70 percent on news that the company was pulling its highly touted and promising new treatment for multiple sclerosis, Tysabri, because two patients using the treatment had developed a rare nervous-system disorder. In the ensuing panic, the company lost billions in market capitalization and was downgraded by a few investment houses.
The drop may represent a real opportunity for investors who have a long-term perspective and understand the company's Nanocrystal technology.
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017